贝伐单抗联合PC化疗方案对非小细胞肺癌患者疾病控制率及生存周期的影响

Effect of Bevacizumab Combined with PC Chemotherapy Regimen on Disease Control Rate and Life Cycle in Patients with Non-small Cell Lung Cancer

目的探究贝伐单抗联合紫杉醇/卡铂(PC)化疗方案对非小细胞肺癌(NSCLC)患者疾病控制率及生存周期的影响。方法选取2014年2月—2015年7月驻马店市第一人民医院非小细胞肺癌患者90例,采用随机数表法分组,各45例。对照组予以卡铂+紫杉醇治疗,观察组予以贝伐单抗+卡铂+紫杉醇治疗,3周为1个周期,共4个周期。对比治疗后两组疾病控制率、无进展生存期及总生存期,统计对比两组不良反应发生率。结果治疗后观察组疾病控制率75.56%(34/45)高于对照组53.33%(24/45),差异有统计学意义(P<0.05);治疗后观察组无进展生存期长于对照组,差异有统计学意义(P<0.05);治疗后观察组总生存期长于对照组,差异有统计学意义(P<0.05);治疗后两组不良反应发生率对比,差异无统计学意义(P>0.05)。结论贝伐单抗联合PC化疗方案治疗NSCLC,可提高疾病控制率,延长患者生存周期,安全性高,值得推广。

Objective To investigate the effect of bevacizumab combined with chemotherapy regimen of paclitaxel/carboplatin（ PC） on the disease control rate and life cycle in patients with non-small cell lung cancer（ NSCLC）.Methods From February 2014 to July 2015,90 cases of patients with non-small cell lung cancer in our hospital were selected and grouped according to the random number table,45 cases in each group. The control group was treated with carboplatin ＋ paclitaxel,and the observation group was treated with bevacizumab ＋ carboplatin ＋ paclitaxel. Both groups were treated for 4 cycles,each cycle including 3 weeks. The disease control rate,progression free life cycle,and overall life cycle were compared between the two groups after treatment. The incidence of adverse reactions was compared between the two groups. Results After treatment,the disease control rate of the observation group was 75. 56%（ 34/45）,which was higher than that of the control group（ 53. 33%）（ 24/45）（ P〈0. 05）. The progression free life cycle of the observation group was longer than that of the control group（ P〈0. 05）. After treatment,the overall life cycle time of the observation group was longer than that of the control group（ P〈0. 05）. There was no significant difference in the incidence of adverse reactions between the two groups after treatment（ P〉0. 05）. Conclusion Bevacizumab combined with PC chemotherapy in the treatment of NSCLC can improve the disease control rate and prolong the life cycle of patients. It has high safety and it is worth promoting.